DOCSLIB.ORG

DHEA and Testosterone in the Elderly

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DHEA and Testosterone in the Elderly correspondence today, according to data from the United Network Dr. Buchanan reports receiving a grant from the American Society of Transplantation. Dr. Schnitzler reports receiving con- for Organ Sharing. sulting fees from Novartis Pharma, lecture fees from Genzyme, Daniel C. Brennan, M.D. and grant support from Genzyme, Novartis Pharma, Astellas, Washington University School of Medicine and TransMedics. St. Louis, MO 63110 [email protected] 1. Humar A, Johnson EM, Payne WD, et al. Effect of initial slow graft function on renal allograft rejection and survival. Clin Paula Buchanan, M.P.H. Transplant 1997;11:623-7. Mark A. Schnitzler, Ph.D. Saint Louis University Center for Outcomes Research St. Louis, MO 63104 DHEA and Testosterone in the Elderly To the Editor: In their report on the effects of Alvin M. Matsumoto, M.D. dehydroepiandrosterone (DHEA) and testosterone Veterans Affairs Puget Sound Health Care System when used as antiaging supplements, Nair et al. Seattle, WA 98108 (Oct. 19 issue)1 conclude that low-dose testoster- William J. Bremner, M.D., Ph.D. one replacement in elderly men has no “physiolog- University of Washington ically relevant beneficial effects on body composi- Seattle, WA 98195 tion, physical performance, [or] insulin sensitivity.” 1. Nair KS, Rizza RA, O’Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006; However, this conclusion is premature, since the 355:1647-59. testosterone replacement administered failed to 2. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testoster- achieve physiologic testosterone levels throughout one treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999;84:2647-53. the study period (Fig. 2 of the article). Moreover, 3. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone despite the marginal increase in testosterone lev- therapy in adult men with androgen deficiency syndromes: an els achieved, improvements in fat-free mass, fast- Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995-2010. [Erratum, J Clin Endocrinol Metab ing insulin levels, and bone mineral density were 2006;91:2688.] observed. 4. Page ST, Amory JK, Bowman FD, et al. Exogenous testoster- Other studies of testosterone replacement, in- one (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. cluding those cited to support the authors’ con- J Clin Endocrinol Metab 2005;90:1502-10. 2 clusions, have shown a decrease in fat mass 5. Amory JK, Watts NB, Easley KA, et al. Exogenous testoster- (12.5%) and an increase in lean mass (4%) when one or testosterone with finasteride increases bone mineral den- sity in older men with low serum testosterone. J Clin Endocrinol physiologic testosterone levels are achieved in el- Metab 2004;89:503-10. derly men. Studies of standard doses of testos- terone in the treatment of testicular failure3 have shown additional positive effects on muscle To the Editor: The findings of Nair et al. can- strength, physical performance,4 and bone min- not be generalized, because the study included eral density.5 Large, long-term trials are clearly relatively healthy subjects. To investigate the ben- needed to assess the risks and benefits of testos- efits and risks of androgen-replacement therapy, terone replacement in elderly men, and caution it is essential to make judicious choices regarding should be exercised regarding the treatment of the subjects to be included in the research. In this andropause in men. However, the serum testos- study, the average baseline scores for the quality terone level achieved should be within the normal of life (on the Health Status Questionnaire [HSQ] range to assess the effect on outcome measures and the Medical Outcomes Study 36-item Short- adequately. Form General Health Survey [SF-36]) of all the Stephanie T. Page, M.D., Ph.D. subjects were above 50 for both the physical and mental components. The average score on both University of Washington 1 Seattle, WA 98195 instruments in the general U.S. population is 50. [email protected] The high scores of these subjects suggest that the n engl j med 356;6 www.nejm.org february 8, 2007 635 Downloaded from www.nejm.org at BOSTON UNIVERSITY on February 5, 2010 . Copyright © 2007 Massachusetts Medical Society. All rights reserved. T h e new england journal o f medicine study included healthier elderly persons than ute for antiaging uses but constitutes a market those who would be representative of the general estimated at more than $600 million per year in elderly population. the United States alone.4 Moreover, physical exercise is expected to im- Thomas T. Perls, M.D. prove and maintain physical functioning in older Boston University Medical Center people.2,3 Not only androgen administration but Boston, MA 02118 also well-designed physical training is needed to [email protected] improve the physical performance of elderly per- 1. U.S. Senate Special Committee on Aging. Swindlers, hucksters sons. The androgen level might be a mediator and snake oil salesman: hype and hope marketing anti-aging that could be elevated by exercise training, which products to seniors. 107th Congress, 1st session. Washington, DC: Government Printing Office, September 10, 2001. would then increase physical performance. The 2. Pierpaoli W, Regelson W. The melatonin miracle: nature’s administration of androgen in the absence of ex- age-reversing, disease-fighting, sex-enhancing hormone. New ercise may not be enough to improve physical York: Pocket Books, 1995. 3. Regelson W, Colman C. The superhormone promise. New performance among the elderly. York: Pocket Books, 1996. Mitsuko Yasuda, M.D., Ph.D. 4. Perls TT, Reisman NR, Olshansky SJ. Provision or distribu- tion of growth hormone for “antiaging”: clinical and legal issues. Shigeo Horie, M.D. JAMA 2005;294:2086-90. Teikyo University Tokyo 173-8605, Japan [email protected] To the Editor: The study by Nair et al. may be 1. van Hooren SA, van Boxtel MPJ, Valentijn SAM, Bosma H, misleading. One problem arises from the age of Ponds RW, Jolles J. Influence of cognitive functioning on func- the persons involved in the study. Women older tional status in an older population: 3- and 6-year follow-up of the Maastricht Aging Study. Int J Geriatr Psychiatry 2005;20: than 60 years rarely have postmenopausal symp- 883-8. toms. In the absence of symptoms, how are the 2. Mian OS, Thom JM, Ardigo LP, et al. Effect of a 12-month beneficial effects of treatment on the quality of life physical conditioning programme on the metabolic cost of walk- ing in healthy older adults. Eur J Appl Physiol (in press). to be demonstrated? Similarly, one may question 3. Tsuji I, Tamagawa A, Nagatomi R, et al. Randomized con- the use of testosterone in men older than 60 years. trolled trial of exercise training for older people (Sendai Silver The principal problem, however, is that Nair Center Trial: SSCT): study design and primary outcome. J Epide- miol 2000;10:55-64. et al. treated laboratory values (low values of DHEA and testosterone), not — as is usual medi- cal practice — symptoms. To return to the exam- To the Editor: DHEA was banned in 1985 by the ple of postmenopausal care for women older than Food and Drug Administration because clinical 60 years, such an approach could be equated with safety and efficacy data were lacking to support indiscriminately treating unselected postmeno- claims of cures for cardiovascular disease and pausal women, all of whom, of course, have low aging. After the passage of the Dietary Supple- estradiol levels, with estrogen replacement, wheth- ment Health and Education Act in 1994, DHEA, er or not they are symptomatic. Whether such an which had not previously been labeled as a drug, unselected approach to treatment would ever re- again became available. It is amazing that a pre- veal clinical benefits regarding the quality of life viously banned substance can now be sold directly is questionable. to the public, and it speaks to the lack of over- That DHEA can indeed positively affect certain sight and protection afforded by the Dietary Sup- physiological processes of aging has been sug- plement Health and Education Act. gested with regard to ovarian function.1-3 Thus, Hormones have long been equated with youth nothing in the study by Nair et al. contradicts by the public and are thus a favorite type of sub- the value of further investigation of DHEA in stance for marketing by the antiaging industry.1 specific conditions of aging. As one substance falls out of favor, another quick- Norbert Gleicher, M.D. 2 ly replaces it: the miracle of melatonin was re- David Barad, M.D. placed by the superhormone promise3 of DHEA. Center for Human Reproduction The heir apparent now seems to be growth hor- New York, NY 10021 mone, which, paradoxically, is illegal to distrib- [email protected] 636 n engl j med 356;6 www.nejm.org february 8, 2007 Downloaded from www.nejm.org at BOSTON UNIVERSITY on February 5, 2010 . Copyright © 2007 Massachusetts Medical Society. All rights reserved. correspondence Drs. Gleicher and Barad are part owners of a pending patent verse events and long-term benefits of restoring involving the use of DHEA for the improvement of ovarian func- tion in women with diminished ovarian function. testosterone levels in older people to levels seen in young people. 1. Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. In response to Yasuda and Horie, the HSQ is Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod 2000; a measure of perceived but not actual health.
Load more

Recommended publications
  • COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone During SARS-Cov-2 Infection
    pharmaceuticals Review COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection Katarzyna Kotfis 1,* , Kacper Lechowicz 1 , Sylwester Drozd˙ zal˙ 2 , Paulina Nied´zwiedzka-Rystwej 3 , Tomasz K. Wojdacz 4, Ewelina Grywalska 5 , Jowita Biernawska 6, Magda Wi´sniewska 7 and Miłosz Parczewski 8 1 Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland; [email protected] 2 Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 3 Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland; [email protected] 4 Independent Clinical Epigenetics Laboratory, Pomeranian Medical University, 71-252 Szczecin, Poland; [email protected] 5 Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 6 Department of Anesthesiology and Intensive Therapy, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland; [email protected] 7 Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 8 Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; [email protected] * Correspondence: katarzyna.kotfi[email protected]; Tel.: +48-91-466-11-44 Abstract: In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared Citation: Kotfis, K.; Lechowicz, K.; a global pandemic by the World Health Organization (WHO). The clinical course of the disease is Drozd˙ zal,˙ S.; Nied´zwiedzka-Rystwej, unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to P.; Wojdacz, T.K.; Grywalska, E.; acute respiratory distress syndrome (ARDS).
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Effect of Dehydroepiandrosterone and Testosterone Supplementation on Systemic Lipolysis
    ORIGINAL ARTICLE Effect of Dehydroepiandrosterone and Testosterone Supplementation on Systemic Lipolysis Ana E. Espinosa De Ycaza, Robert A. Rizza, K. Sreekumaran Nair, and Michael D. Jensen Division of Endocrinology, Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905 Downloaded from https://academic.oup.com/jcem/article/101/4/1719/2804555 by guest on 24 September 2021 Context: Dehydroepiandrosterone (DHEA) and T hormones are advertised as antiaging, antiobe- sity products. However, the evidence that these hormones have beneficial effects on adipose tissue metabolism is limited. Objective: The objective of the study was to determine the effect of DHEA and T supplementation on systemic lipolysis during a mixed-meal tolerance test (MMTT) and an iv glucose tolerance test (IVGTT). Design: This was a 2-year randomized, double-blind, placebo-controlled trial. Setting: The study was conducted at a general clinical research center. Participants: Sixty elderly women with low DHEA concentrations and 92 elderly men with low DHEA and bioavailable T concentrations participated in the study. Interventions: Elderly women received 50 mg DHEA (n ϭ 30) or placebo (n ϭ 30). Elderly men received 75 mg DHEA (n ϭ 30),5mgT(nϭ 30), or placebo (n ϭ 32). Main Outcome Measures: In vivo measures of systemic lipolysis (palmitate rate of appearance) during a MMTT or IVGTT. Results: At baseline there was no difference in insulin suppression of lipolysis measured during MMTT and IVGTT between the treatment groups and placebo. For both sexes, a univariate analysis showed no difference in changes in systemic lipolysis during the MMTT or IVGTT in the DHEA group and T group when compared with placebo.
    [Show full text]
  • Reproductive DHEA-S
    Reproductive DHEA-S Analyte Information - 1 - DHEA-S Introduction DHEA-S, DHEA sulfate or dehydroepiandrosterone sulfate, it is a metabolite of dehydroepiandrosterone (DHEA) resulting from the addition of a sulfate group. It is the sulfate form of aromatic C19 steroid with 10,13-dimethyl, 3-hydroxy group and 17-ketone. Its chemical name is 3β-hydroxy-5-androsten-17-one sulfate, its summary formula is C19H28O5S and its molecular weight (Mr) is 368.5 Da. The structural formula of DHEA-S is shown in (Fig.1). Fig.1: Structural formula of DHEA-S Other names used for DHEA-S include: Dehydroisoandrosterone sulfate, (3beta)-3- (sulfooxy), androst-5-en-17-one, 3beta-hydroxy-androst-5-en-17-one hydrogen sulfate, Prasterone sulfate and so on. As DHEA-S is very closely connected with DHEA, both hormones are mentioned together in the following text. Biosynthesis DHEA-S is the major C19 steroid and is a precursor in testosterone and estrogen biosynthesis. DHEA-S originates almost exclusively in the zona reticularis of the adrenal cortex (Fig.2). Some may be produced by the testes, none is produced by the ovaries. The adrenal gland is the sole source of this steroid in women, whereas in men the testes secrete 5% of DHEA-S and 10 – 20% of DHEA. The production of DHEA-S and DHEA is regulated by adrenocorticotropin (ACTH). Corticotropin-releasing hormone (CRH) and, to a lesser extent, arginine vasopressin (AVP) stimulate the release of adrenocorticotropin (ACTH) from the anterior pituitary gland (Fig.3). In turn, ACTH stimulates the adrenal cortex to secrete DHEA and DHEA-S, in addition to cortisol.
    [Show full text]
  • Safety Data Sheet
    SAFETY DATA SHEET SECTION 1: PRODUCT IDENTIFICATION PRODUCT NAME DHEA (Prasterone) (Micronized) PRODUCT CODE 0733 SUPPLIER MEDISCA Inc. Tel.: 1.800.932.1039 | Fax.: 1.855.850.5855 661 Route 3, Unit C, Plattsburgh, NY, 12901 3955 W. Mesa Vista Ave., Unit A-10, Las Vegas, NV, 89118 6641 N. Belt Line Road, Suite 130, Irving, TX, 75063 MEDISCA Pharmaceutique Inc. Tel.: 1.800.665.6334 | Fax.: 514.338.1693 4509 Rue Dobrin, St. Laurent, QC, H4R 2L8 21300 Gordon Way, Unit 153/158, Richmond, BC V6W 1M2 MEDISCA Australia PTY LTD Tel.: 1.300.786.392 | Fax.: 61.2.9700.9047 Unit 7, Heritage Business Park 5-9 Ricketty Street, Mascot, NSW 2020 EMERGENCY PHONE CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300 NSW Poisons Information Centre: 131 126 USES Adjuvant; Androgen SECTION 2: HAZARDS IDENTIFICATION GHS CLASSIFICATION Toxic to Reproduction (Category 2) PICTOGRAM SIGNAL WORD Warning HAZARD STATEMENT(S) Reproductive effector, prohormone. Suspected of damaging fertility or the unborn child. May cause harm to breast-fed children. Causes serious eye irritation. Causes skin and respiratory irritation. Very toxic to aquatic life with long lasting effects. AUSTRALIA-ONLY HAZARDS Not Applicable. PRECAUTIONARY STATEMENT(S) Prevention Wash thoroughly after handling. Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe dusts or mists. Do not eat, drink or smoke when using this product. Avoid contact during pregnancy/while nursing. Wear protective gloves, protective clothing, eye protection, face protection. Avoid release to the environment. Response IF ON SKIN (HAIR): Wash with plenty of water.
    [Show full text]
  • A10 Anabolic Steroids Hardcore Info
    CONTENTS GENERAL INFORMATION 3 Anabolic steroids – What are they? 4 How do they Work? – Aromatisation 5 More molecules – More problems 6 The side effects of anabolic steroids 7 Women and anabolic steroids 8 Injecting steroids 9 Abscesses – Needle Exchanges 10 Intramuscular injection 11 Injection sites 12 Oral steroids – Cycles – Stacking 13 Diet 14 Where do steroids come from? Spotting a counterfeit 15 Drug Information – Drug dosage STEROIDS 16 Anadrol – Andriol 17 Anavar – Deca-Durabolin 18 Dynabolon – Durabolin – Dianabol 19 Esiclene – Equipoise 20 Primobolan Depot – Proviron – Primobolan orals – Pronobol 21 Sustanon – Stromba, Strombaject – Testosterone Cypionate Testosterone Enanthate 22 Testosterone Propionate – Testosterone Suspension 23 Trenbolone Acetate – Winstrol OTHER DRUGS 24 Aldactone – Arimidex 25 Clenbuterol – Cytomel 26 Ephedrine Hydrochloride – GHB 27 Growth Hormone 28 Insulin 30 Insulin-Like Growth Factor-1 – Human Chorionic Gonadotrophin 31 Tamoxifen – Nubain – Recreational Drugs 32 Steroids and the Law 34 Glossary ANABOLIC STEROIDS People use anabolic steroids for various reasons, some use them to build muscle for their job, others just want to look good and some use them to help them in sport or body building. Whatever the reason, care needs to be taken so that as little harm is done to the body as possible because despite having muscle building effects they also have serious side effects especially when used incorrectly. WHAT ARE THEY? Anabolic steroids are man made versions of the hormone testosterone. Testosterone is the chemical in men responsible for facial hair, deepening of the voice and sex organ development, basically the masculine things Steroids are in a man. used in medicine to treat anaemia, muscle weakness after These masculine effects surgery etc, vascular are called the androgenic disorders and effects of testosterone.
    [Show full text]
  • Gender-Affirming Hormone Therapy
    GENDER-AFFIRMING HORMONE THERAPY Julie Thompson, PA-C Medical Director of Trans Health, Fenway Health March 2020 fenwayhealth.org GOALS AND OBJECTIVES 1. Review process of initiating hormone therapy through the informed consent model 2. Provide an overview of masculinizing and feminizing hormone therapy 3. Review realistic expectations and benefits of hormone therapy vs their associated risks 4. Discuss recommendations for monitoring fenwayhealth.org PROTOCOLS AND STANDARDS OF CARE fenwayhealth.org WPATH STANDARDS OF CARE, 2011 The criteria for hormone therapy are as follows: 1. Well-documented, persistent (at least 6mo) gender dysphoria 2. Capacity to make a fully informed decision and to consent for treatment 3. Age of majority in a given country 4. If significant medical or mental health concerns are present, they must be reasonably well controlled fenwayhealth.org INFORMED CONSENT MODEL ▪ Requires healthcare provider to ▪ Effectively communicate benefits, risks and alternatives of treatment to patient ▪ Assess that the patient is able to understand and consent to the treatment ▪ Informed consent model does not preclude mental health care! ▪ Recognizes that prescribing decision ultimately rests with clinical judgment of provider working together with the patient ▪ Recognizes patient autonomy and empowers self-agency ▪ Decreases barriers to medically necessary care fenwayhealth.org INITIAL VISITS ▪ Review history of gender experience and patient’s goals ▪ Document prior hormone use ▪ Assess appropriateness for gender affirming medical
    [Show full text]
  • DHEA Sulfate, and Aging: Contribution of the Dheage Study to a Sociobiomedical Issue
    Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue Etienne-Emile Baulieua,b, Guy Thomasc, Sylvie Legraind, Najiba Lahloue, Marc Rogere, Brigitte Debuiref, Veronique Faucounaug, Laurence Girardh, Marie-Pierre Hervyi, Florence Latourj, Marie-Ce´ line Leaudk, Amina Mokranel, He´ le` ne Pitti-Ferrandim, Christophe Trivallef, Olivier de Lacharrie` ren, Stephanie Nouveaun, Brigitte Rakoto-Arisono, Jean-Claude Souberbiellep, Jocelyne Raisonq, Yves Le Boucr, Agathe Raynaudr, Xavier Girerdq, and Franc¸oise Foretteg,j aInstitut National de la Sante´et de la Recherche Me´dicale Unit 488 and Colle`ge de France, 94276 Le Kremlin-Biceˆtre, France; cInstitut National de la Sante´et de la Recherche Me´dicale Unit 444, Hoˆpital Saint-Antoine, 75012 Paris, France; dHoˆpital Bichat, 75877 Paris, France; eHoˆpital Saint-Vincent de Paul, 75014 Paris, France; fHoˆpital Paul Brousse, 94804 Villejuif, France; gFondation Nationale de Ge´rontologie, 75016 Paris, France; hHoˆpital Charles Foix, 94205 Ivry, France; iHoˆpital de Biceˆtre, 94275 Biceˆtre, France; jHoˆpital Broca, 75013 Paris, France; kCentre Jack-Senet, 75015 Paris, France; lHoˆpital Sainte-Perine, 75016 Paris, France; mObservatoire de l’Age, 75017 Paris, France; nL’Ore´al, 92583 Clichy, France; oInstitut de Sexologie, 75116 Paris, France; pHoˆpital Necker, 75015 Paris, France; qHoˆpital Broussais, 75014 Paris, France; and rHoˆpital Trousseau, 75012 Paris, France Contributed by Etienne-Emile Baulieu, December 23, 1999 The secretion and the blood levels of the adrenal steroid dehydro- number of consumers. Extravagant publicity based on fantasy epiandrosterone (DHEA) and its sulfate ester (DHEAS) decrease pro- (‘‘fountain of youth,’’ ‘‘miracle pill’’) or pseudoscientific asser- foundly with age, and the question is posed whether administration tion (‘‘mother hormone,’’ ‘‘antidote for aging’’) has led to of the steroid to compensate for the decline counteracts defects unfounded radical assertions, from superactivity (‘‘keep young,’’ associated with aging.
    [Show full text]
  • Treated with Steroids Derived from Dehydroepiandrosterone
    Proc. Natl. Acad. Sci. USA Vol. 92, pp. 6617-6619, July 1995 Medical Sciences Ergosteroids: Induction of thermogenic enzymes in liver of rats treated with steroids derived from dehydroepiandrosterone HENRY LARDY, BRUCE PARTRIDGE, NANCY KNEER, AND YONG WEI Institute for Enzyme Research, University of Wisconsin, 1710 University Avenue, Madison, WI 53705 Contributed by Henry Lardy, April 24, 1995 ABSTRACT Dehydroepiandrosterone (DHEA), an inter- above normal concentrations (16); they become hirsute and mediate in the biosynthesis of testosterone and estrogens, exhibit other signs of masculinization. exerts several physiological effects not involving the sex It was demonstrated by Tagliaferro et al. (20) that feeding hormones. When fed to rats it induces the thermogenic DHEA to rats enhanced heat production and decreased enzymes mitochondrial sn-glycerol-3-phosphate dehydroge- efficiency of food utilization. We therefore measured its effect nase and cytosolic malic enzyme in their livers. Animals and on the production of liver mitochondrial sn-glycerol-3- humans, and their excised tissues, are known to hydroxylate phosphate dehydrogenase and cytosolic malic enzyme, two DHEA at several positions and to interconvert 7a-hydroxy- enzymes that had been demonstrated (21-24) to be induced by DHEA, 7,8-hydroxy-DHEA, 7-oxo-DHEA, and the correspond- a classic thermogenic agent, the thyroid hormone. Both en- ing derivatives of androst-5-enediol. We report here that these zymes were increased severalfold in livers of rats fed a diet 7-oxygenated derivatives are active inducers of these thermo- containing 0.2-0.5% DHEA for 6 days (25, 26). A possible genic enzymes in rats and that the 7-oxo derivatives are more mechanism by which these enzymes function to decrease active than the parent steroids.
    [Show full text]
  • Low Testosterone (Hypogonadism)
    Low Testosterone (Hypogonadism) Testosterone is an anabolic-androgenic steroid hormone which is made in the testes in males (a minimal amount is also made in the adrenal glands). Testosterone has two major functions in the human body. Testosterone production is regulated by hormones released from the brain. The brain and testes work together to keep testosterone in the normal range (between 199 ng/dL and 1586 ng/dL) Testosterone is needed to form and maintain the male sex organs, regulate sex drive (libido) and promote secondary male sex characteristics such as voice deepening and development of facial and body hair. Testosterone facilitates muscle growth as well as bone development and maintenance. Low testosterone levels in the blood are seen in males with a medical condition known as Hypogonadism. This may be due to a signaling problem between the brain and testes that can cause production to slow or stop. Hypogonadism can also be caused by a problem with production in the testes themselves. Causes Primary: This type of hypogonadism — also known as primary testicular failure — originates from a problem in the testicles. Secondary: This type of hypogonadism indicates a problem in the hypothalamus or the pituitary gland — parts of the brain that signal the testicles to produce testosterone. The hypothalamus produces gonadotropin- releasing hormone, which signals the pituitary gland to make follicle-stimulating hormone (FSH) and luteinizing hormone. Luteinizing hormone then signals the testes to produce testosterone. Either type of hypogonadism may be caused by an inherited (congenital) trait or something that happens later in life (acquired), such as an injury or an infection.
    [Show full text]
  • Development of a Derivatization Method for Investigating
    Scientia Pharmaceutica Article Development of a Derivatization Method for Investigating Testosterone and Dehydroepiandrosterone Using Tandem Mass Spectrometry in Saliva Samples from Young Professional Soccer Players Pre- and Post-Training Mansour A. Alzahrani 1,*, Ghareeb O. Alshuwaier 2, Khalid S. Aljaloud 2 , Colin Gibson 3, Abedawn Khalaf 3, Aliyah S. Alhawiti 1 and David G. Watson 1,* 1 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, The John Arbuthnott Building, 161 Cathedral Street, Glasgow G4 0RE, UK; [email protected] 2 College of Sports Sciences and Physical Activity, King Saud University, Building 69, Code 11441, Riyadh P.O. Box 1949, Saudi Arabia; [email protected] (G.O.A.); [email protected] (K.S.A.) 3 Department of Pure and Applied Chemistry, University of Strathclyde, 295 Cathedral Street, Glasgow G1 1XL, UK; [email protected] (C.G.); [email protected] (A.K.) * Correspondence: [email protected] (M.A.A.); [email protected] (D.G.W.) Received: 7 March 2019; Accepted: 3 April 2019; Published: 19 April 2019 Abstract: In the last decade, high-performance liquid chromatography/tandem mass spectrometry (LC/MS/MS) combined with electrospray ionization (ESI) has been widely used for determining low concentrations of steroids, and derivatization has often been employed to enhance detection. In the present study, endogenous steroids were extracted using a Strata-XL polymeric reverse phase cartridge. The isolated steroids were reacted with 2-hydrazino-1-methylpyridine (HMP) at 50 ◦C for 30 min. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used in a positive mode with multiple reaction monitoring (MRM) for the quantification of testosterone (T) and its precursor, dehydroepiandrosterone (DHEA), in saliva samples collected from twenty young Saudi professional soccer players.
    [Show full text]
  • Improving Low Testosterone Naturally
    IMPROVING LOW TESTOSTERONE NATURALLY The following information is a summary of materials featured in the “Men’s Health” Whole Health overview. It is meant to be a quick reference for use at the point of care. For additional details and a list of helpful references, refer to the overview. Hormones change as we go through the life cycle. What is normal for a 20-year-old is not the same normal as for a 60-year-old. Although low testosterone ("low T") is a diagnosis being promoted by the makers of testosterone medications, it is not as simple as just prescribing hormone replacement. A low testosterone level can be due to many factors. A clinician must also take care not to add testosterone too quickly without exploring other therapies first, because once external testosterone is given, it inhibits the body's natural production of testosterone. Testosterone supplementation is also not without risks, and in terms of long-term use, there is much about safety that we do not yet know. KEY FACTORS IN OPTIMIZING MALE HORMONES MAINTAIN IDEAL BODY WEIGHT This is probably the most important thing a man can do. As belly fat increases, there is an increase in activity of the enzyme "aromatase" which converts testosterone in the fat cells to estrogen. This reduces testosterone and increases estrogen, which can increase fat deposition in typical female areas (breast, hips, thighs) and increase the risk of enlargement of the prostate and even prostate cancer. With every one-point drop in your body mass index (BMI) your testosterone level will increase by approximately 1 point.
    [Show full text]